Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Completed · Phase 4 · Has a placebo group

Conditions studied: Attention Deficit Disorder With Hyperactivity

In brief

All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will have an Event related potential (ERP) (a type of electroencephalogram \[EEG\]) study. After the baseline EEG, children will be randomized to either placebo or GXR for a 4-week, parallel groups trial. During this trial, dosing will be flexibly adjusted according to patient response or presence of side effects. The dosage will range from 1-4 mg. At the end of the four week trial, a follow up ERP study will be obtained.

Key facts

Study ID

NCT01069523

Run by

The University of Texas Health Science Center at San Antonio

People needed

42

Starts

2010-03-01

Expected to finish

2011-08-01

Last updated by the study team

2012-09-03

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 6-12 years
• Meet criteria for Attention Deficit Hyperactivity Disorder

You may not qualify if…

• Do not meet criteria for Major Depression, Bipolar, Autism
• Talking any psychotropic medication for a condition other than ADHD
• History of epilepsy, severe head injury or loss of consciousness
• History of Intolerance to guanfacine

Where it is running

• Dept. Of Psychiatry, University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.